Advertisement

Pharmacogenetics in the Field of Heme Metabolism: Drug Sensitivity in Hereditary Hepatic Porphyria

  • J. Douglas Maxwell
  • Urs A. Meyer
Chapter
Part of the Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology book series (HEP, volume 44)

Abstract

Sir Archibald Garrod (1902), who pioneered the study of inborn errors of metabolism, was the first to suggest that unusual reactions to drugs might be caused by genetically determined aberrations in metabolic pathways. This far-sighted observation was neglected for many years. However, with the recognition in the 1950’s that several “idiosyncratic” drug reactions, such as primaquine-induced hemolytic anemia and suxamethonium-induced prolonged apnoea, could be explained on the basis of genetically determined enzyme deficiencies, pharmacogenetics was established. Initially, the term referred only to hereditary disorders involving adverse reactions to drugs that were uncovered by administration of the particular agents. This definition seemed too restrictive, as it excluded from consideration genetically determined differences in drug metabolism or disposition (pharmacokinetics) and drug response (pharmacodynamics) between healthy non-medicated subjects (Vesell, 1975). When it became apparent that the interplay between genetics and pharmacology influenced the action of many drugs, the scope of pharmacogenetics was extended to include all studies at the interface of these two sciences. Pharmacogenetics now incorporates all clinically important hereditary variations in drug metabolism and response.

Keywords

Acute Attack Heme Biosynthesis Porphyria Cutanea Tarda Heme Synthesis Intermittent Acute Porphyria 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson, K.E., Alvarez, A.P., Sassa, S., Kappas, A.: Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria. Clin. Pharmacol. Ther. 19, 47–54 (1976)PubMedGoogle Scholar
  2. Beattie, A.D., Moore, M.R., Goldberg, A., Ward, R.L.: Acute intermittent porphyria: Response of tachycardia and hypertension to propranolol. Brit. med. J. 1973 III, 257–260CrossRefGoogle Scholar
  3. Bock, K.W., Weiner, R., Frohling, W.: Regulation of δ-aminolevulinate synthetase by steroids and drugs in isolated perfused rat liver. Enzyme 16, 295–301 (1973)PubMedGoogle Scholar
  4. Conney, A.H.: Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19, 317–366(1967)PubMedGoogle Scholar
  5. Correia, M.A., Meyer, U.A.: Apocytochrome P-450: Reconstitution of functional cytochrome with hemin in vitro. Proc. nat. Acad. Sci. (Wash.) 72, 400–404 (1975)CrossRefGoogle Scholar
  6. Dagg, J.H., Goldberg, A., Lochhead, A., Smith, J.A.: The relationship of lead poisoning to acute intermittent porphyria. Quart. J. Med. 34, 163–175 (1965)PubMedGoogle Scholar
  7. Dean, G.: The prevalence of the porphyrias. S. Afr. J. Lab. clin. Med. 9, 145–151 (1963)Google Scholar
  8. De Matteis, F.: Drugs and porphyria. S. Afr. med. J. 45, 126–133 (1971a)Google Scholar
  9. De Matteis, F.: Loss of heme in rat liver caused by the porphyrogenic agent 2-allyl-2-isopro-pylacetamide. Biochem. J. 124, 767–777 (1971b)PubMedGoogle Scholar
  10. De Matteis, F.: Drug-induced destruction of cytochrome P-450. Drug Metab. Dispos. 1, 267–272 (1973a)PubMedGoogle Scholar
  11. De Matteis, F.: Drug interactions in experimental hepatic porphyria: A model for the exacerbation by drugs of human variegate porphyria. Enzyme 16, 266–275 (1973b)PubMedGoogle Scholar
  12. De Matteis, F., Gibbs, A.H.: Stimulation of liver δ-aminolaevulinate synthetase by drugs and its relevance to drug-induced accumulation of cytochrome P-450. Biochem. J. 126, 1149–1160 (1972)PubMedGoogle Scholar
  13. Dhar, G.J., Bossenmaier, I., Petryka, Z.J., Cardinal, R., Watson, C.J.: Effects of hematin in hepatic porphyria. Further studies. Ann. intern. Med. 83, 20–30 (1975)PubMedGoogle Scholar
  14. Dobrschansky, M.: Einiges über Malonal. Wien med. Presse 47, 2145–2151 (1906)Google Scholar
  15. Eales, L.: Acute porphyria: The precipitating and aggravating factors. S. Afr. med. J. 45, 120–125 (1971)Google Scholar
  16. Elder, G.H., Gray, C.H., Nicholson, D.C.: The porphyrias: a review. J. clin. Path. 25, 1013–1033 (1972)PubMedCrossRefGoogle Scholar
  17. Garrod, A.E.: The incidence of alkaptonuria: A study in chemical individuality. Lancet 1902 II, 1616–1620CrossRefGoogle Scholar
  18. Goldberg, A.: Acute intermittent porphyria. Quart. J. Med. 28, 183–209 (1959)PubMedGoogle Scholar
  19. Goldberg, A.: Lead poisoning and heme biosynthesis. Brit. J. Haemat. 23, 521–524 (1972)PubMedCrossRefGoogle Scholar
  20. Granick, S.: The induction in vitro of the synthesis of δ-aminolaevulinic acid synthetase in chemical porphyria. A response to certain drugs, sex hormones, and foreign chemicals. J. biol. Chem. 241, 1359–1375 (1966)PubMedGoogle Scholar
  21. Kaufman, L., Swanson, A.L., Marver, H.S.: Chemically induced porphyria: Prevention by prior treatment with phenobarbital. Science 170, 320–322 (1970)PubMedCrossRefGoogle Scholar
  22. Maxwell, J.D., Meyer, U.A.: Drug sensitivity in hepatic porphyria: Relationship to defect in heme synthesis. J. clin. Invest. 53, 51A (1974)Google Scholar
  23. Maxwell, J.D., Meyer, U.A.: Effect of lead on hepatic δ-aminolaevulinic acid synthetase activity in the rat: A model for drug sensitivity in intermittent acute porphyria. Europ. J. clin. Invest. 6, 373–379(1976)PubMedCrossRefGoogle Scholar
  24. McIntyre, N., Pearson, A.J.G., Allan, D.J., Craske, S., West, G.M.L., Moore, M.R., Paxton, J., Beattie, A.D., Goldberg, A.: Hepatic δ-aminolaevulinic acid synthetase in an attack of hereditary coproporphyria and during remission. Lancet 1971 I, 560–564CrossRefGoogle Scholar
  25. Meyer, U.A.: Intermittent acute porphyria: Clinical and biochemical studies of disordered heme biosynthesis. Enzyme 16, 334–342 (1973)PubMedGoogle Scholar
  26. Meyer, U.A., Marver, H.S.: Chemically induced porphyria: increased microsomal heme turnover after treatment with allyl isopropylacetamide. Science 171, 64–66 (1971)PubMedCrossRefGoogle Scholar
  27. Meyer, U.A., Meier, P.J., Correia, A.M.: Interaction between mitochondria and rough endoplasmic reticulum during induction of cytochrome P-450. In: The Liver. Quantitative Aspects of Structure and Function. Preisig, R., Bircher, J., Paumgartner, G. (eds.), pp. 172–178. Aulendorf, Germany: Editio Cantor 1976Google Scholar
  28. Meyer, U.A., Schmid, R.: Hereditary hepatic porphyrias. Fed. Proc. 32, 1649–1655 (1973)PubMedGoogle Scholar
  29. Meyer, U.A., Schmid, R.: Intermittent acute porphyria. Res. Publ. Ass. nerv. ment. Dis. 33, 211–223 (1974)Google Scholar
  30. Meyer, U.A., Schmid, R.: The porphyrias. In: The Metabolic Basis of Inherited Disease. Stanbury, J.B., Wyngaarden, J.B., Frederickson, D.S. (eds.), 4th edit. New York: McGraw-Hill 1977Google Scholar
  31. Meyer, U.A., Strand, L.T., Doss, M., Rees, A.C., Marver, H.S.: Intermittent acute porphyria: Demonstration of a genetic defect in porphobilinogen metabolism. New Engl. J. Med. 286, 1277–1282 (1972)PubMedCrossRefGoogle Scholar
  32. Padmanaban, G., Rao, M.R.S., Malathi, K.: A model for the regulation of δ-aminolevulinate synthetase induction in rat liver. Biochem. J. 134, 847–857 (1973)PubMedGoogle Scholar
  33. Rajamanickam, C., Rao, M.R.S., Padmanaban, G.: On the sequence of reactions leading to cytochrome P-450 synthesis. Effect of drugs. J. biol. Chem. 250, 2305–2310 (1975)PubMedGoogle Scholar
  34. Ridley, A.: The neuropathology of acute intermittent porphyria. Quart. J. Med. 38, 307–333 (1969)PubMedGoogle Scholar
  35. Rifkind, A.B., Gillette, P.N., Song, C.S., Kappas, A.: Drug stimulation of δ-aminolevulinic acid synthetase and cytochrome P-450 in vivo in chick embryo liver. J. Pharmacol. exp. Ther. 185, 214–225 (1973)PubMedGoogle Scholar
  36. Rimington, C., Magnus, I.A., Ryan, E.A., Cripps, D.J.: Porphyria and photosensitivity. Quart. J. Med. 36, 29–57 (1967)Google Scholar
  37. Sassa, S., Granick, S.: Induction of δ-aminolevulinic acid synthetase in chick embryo liver cells in culture. Proc. nat. Acad. Sci. (Wash.) 67, 517–522 (1970)CrossRefGoogle Scholar
  38. Schmid, R.: Discussion of paper by De Matteis, F. Drug Metab. Dispos. 1, 273 (1973)Google Scholar
  39. Sinclair, P.R., Granick, S.: Heme control of the synthesis of δ -aminolevulinic acid synthetase in cultured chick embryo liver cells. Ann. N.Y. Acad. Sci. 244, 509–520 (1975)PubMedCrossRefGoogle Scholar
  40. Song, C.S., Bonkowsky, H.L., Tschudy, D.P.: Salicylamide metabolism in acute intermittent porphyria. Clin. Pharmacol. Ther. 15, 431–435 (1974)PubMedGoogle Scholar
  41. Stein, J.A., Tschudy, D.P.: Acute intermittent porphyria: A clinical and biochemical study of 46 patients. Medicine (Baltimore) 49, 1–16 (1970)Google Scholar
  42. Strand, J.L., Felsher, B.F., Redeker, A.G., Marver, H.S.: Heme biosynthesis in intermittent acute porphyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased δ-aminolevulinic acid synthetase activity. Proc. nat. Acad. Sci. (Wash.) 67, 1315–1320 (1970)CrossRefGoogle Scholar
  43. Strand, J.L., Manning, J., Marver, H.S.: The induction of δ-aminolevulinic acid synthetase in cultured liver cells. J. biol. Chem. 247, 2820–2827 (1972)PubMedGoogle Scholar
  44. Taddeini, L., Watson, C.J.: The clinical porphyrias. Sem. Hemat. 5, 335–369 (1968)Google Scholar
  45. Tschudy, D.P., Bonkowsky, H.L.: Experimental porphyria. Fed. Proc. 31, 147–159 (1972)PubMedGoogle Scholar
  46. Vesell, E.S.: Pharmacogenetics. Biochem. Pharmacol. 24, 445–450 (1975PubMedCrossRefGoogle Scholar
  47. Waldenstrom, J.: Studien über Porphyrie. Acta med. scand. Suppl. 82 (1937)Google Scholar
  48. Watson, C.T.: Haematin and porphyria. New Engl. J. Med. 293, 605–607 (1975)PubMedCrossRefGoogle Scholar
  49. With, T.K.: Acute intermittent porphyria: Family studies on the excretion of PBG and delta-ALA with ion exchange chromatography. Z. klin. Chem. 1, 134–143 (1963)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1978

Authors and Affiliations

  • J. Douglas Maxwell
  • Urs A. Meyer

There are no affiliations available

Personalised recommendations